Pensionfund Sabic Invests $1.32 Million in Zoetis Inc. $ZTS

Key Points

• Pensionfund Sabic acquired a new stake of 10,500 shares in Zoetis in Q4, valued at approximately $1.32 million.
• Zoetis beat earnings with $1.48 EPS vs. a $1.40 estimate and $2.39B in revenue, and set FY2026 guidance of $7.00–$7.10 EPS (consensus ~6.07 EPS).
• The company announced a quarterly dividend of $0.53 (annualized $2.12, ~1.8% yield; ex-dividend Apr 20), institutional investors own 92.8% of shares, and analyst consensus is a Hold with a $152.91 price target.

Pensionfund Sabic acquired a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,500 shares of the company's stock, valued at approximately $1,321,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. North Star Asset Management Inc. grew its holdings in shares of Zoetis by 4.9% during the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company's stock valued at $225,000 after buying an additional 67 shares during the last quarter. Bank of Nova Scotia Trust Co. raised its stake in Zoetis by 4.6% in the 2nd quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company's stock worth $264,000 after acquiring an additional 74 shares during the last quarter. Summit Place Financial Advisors LLC lifted its position in Zoetis by 0.4% during the 3rd quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company's stock worth $2,834,000 after acquiring an additional 76 shares during the period. First County Bank CT lifted its position in Zoetis by 5.4% during the 3rd quarter. First County Bank CT now owns 1,535 shares of the company's stock worth $225,000 after acquiring an additional 79 shares during the period. Finally, CWA Asset Management Group LLC grew its stake in Zoetis by 1.1% during the 3rd quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company's stock valued at $1,059,000 after purchasing an additional 80 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Stock Up 0.6%

ZTS opened at $115.94 on Wednesday. The company has a fifty day moving average of $123.97 and a two-hundred day moving average of $129.76. The stock has a market capitalization of $48.94 billion, a price-to-earnings ratio of 19.26, a PEG ratio of 1.76 and a beta of 0.95. Zoetis Inc. has a fifty-two week low of $113.30 and a fifty-two week high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period in the prior year, the company posted $1.40 EPS. The company's revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis's dividend payout ratio (DPR) is presently 35.22%.

Analyst Ratings Changes

Several brokerages have recently issued reports on ZTS. Weiss Ratings upgraded Zoetis from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, March 12th. Leerink Partners reissued a "market perform" rating on shares of Zoetis in a research report on Tuesday, March 10th. Piper Sandler restated a "neutral" rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. Finally, The Goldman Sachs Group upgraded shares of Zoetis to a "buy" rating in a research note on Monday, December 15th. Six analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.